Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.76 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.76 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | MDH1 | P40925 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | LPL | P06858 | 1/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15174613 | 1.00 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2MDH1PPARG | |
| SCHEMBL15174508 | 1.00 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2MDH1PPARG | |
| SCHEMBL1792728 | 0.94 | CYP4A11 (0.75) | CYP4F2CYP4A11LOXL2MDH1SLC7A5 | |
| SCHEMBL20034122 | 0.90 | CYP4F2 (0.61) | CYP4F2CYP4A11LOXL2MDH1PPARG | |
| SCHEMBL31752933 | 0.88 | CYP4A11 (0.97) | CYP4F2CYP4A11LOXL2SLC7A5 | |
| SCHEMBL19078992 | 0.88 | CYP4A11 (0.76) | CYP4F2CYP4A11LOXL2MDH1SLC7A5 | |
| SCHEMBL1696378 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2MDH1SLC7A5 | |
| SCHEMBL20178551 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11PPARGPPARASPHK2 | |
| SCHEMBL19889923 | 0.87 | CYP4F2 (0.74) | CYP4F2CYP4A11LOXL2SLC7A5 | |
| SCHEMBL18540811 | 0.86 | CYP4A11 (1.00) | CYP4F2CYP4A11LOXL2MDH1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263742-A1 | A LIPID | CETP, PLIN1, AUP1 | CYP4F2 1444/4885CYP4A11 2063/4885LOXL2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.